Compare Johnson & Johnson (JNJ) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Weibo Corp — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: Johnson & Johnson is far larger — about 396.2× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Weibo Corp for 102 Days on average.
| JNJ | WB | |
|---|---|---|
Market Cap | $618.09B | $1.56B |
Volume | 6,050,983 | 812,503 |
Sector | Health | Media |
52-Week High | $278.43 | $11.61 |
52-Week Low | $186.00 | $6.33 |
Typical Hold Time | 129 Days | 102 Days |
Enterprise Value | $646.37B | $786.69M |
Dividend Yield | 2.09% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Weibo (WB) trades at $6.44, down 0.62% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 5.32 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing. Cash flow trends indicate volatility with 2024 showing negative net cash flow of $694M despite solid operational performance.
Weibo presents a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 41% buy ratings versus 14% sell. Key risks include competitive pressures in social media and China's regulatory environment, while the current price near support levels offers potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
